NASDAQ:CLRB Cellectar Biosciences (CLRB) Stock Forecast, Price & News $2.64 +0.10 (+3.94%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$2.52▼$2.7750-Day Range$1.60▼$2.6452-Week Range$1.25▼$3.70Volume190,657 shsAverage Volume1.99 million shsMarket Capitalization$25.71 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Cellectar Biosciences MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside165.2% Upside$7.00 Price TargetShort InterestBearish5.23% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.29Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.23) to ($2.00) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.85 out of 5 starsMedical Sector758th out of 970 stocksPharmaceutical Preparations Industry360th out of 450 stocks 3.5 Analyst's Opinion Consensus RatingCellectar Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.00, Cellectar Biosciences has a forecasted upside of 165.2% from its current price of $2.64.Amount of Analyst CoverageCellectar Biosciences has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.23% of the float of Cellectar Biosciences has been sold short.Short Interest Ratio / Days to CoverCellectar Biosciences has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cellectar Biosciences has recently increased by 238.39%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCellectar Biosciences does not currently pay a dividend.Dividend GrowthCellectar Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CLRB. Previous Next 2.9 News and Social Media Coverage News SentimentCellectar Biosciences has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Cellectar Biosciences this week, compared to 0 articles on an average week.Search Interest3 people have searched for CLRB on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows1 people have added Cellectar Biosciences to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cellectar Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.10% of the stock of Cellectar Biosciences is held by insiders.Percentage Held by InstitutionsOnly 16.41% of the stock of Cellectar Biosciences is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cellectar Biosciences are expected to grow in the coming year, from ($2.23) to ($2.00) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cellectar Biosciences is -0.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cellectar Biosciences is -0.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCellectar Biosciences has a P/B Ratio of 1.75. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Cellectar Biosciences (NASDAQ:CLRB) StockCellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r pediatric patients with head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.Read More CLRB Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CLRB Stock News HeadlinesSeptember 29, 2023 | americanbankingnews.comCellectar Biosciences (NASDAQ:CLRB) Research Coverage Started at StockNews.comSeptember 21, 2023 | americanbankingnews.comCellectar Biosciences (NASDAQ:CLRB) Share Price Passes Above 50-Day Moving Average of $1.90September 30, 2023 | Chaikin Analytics (Ad)Wall Street Legend Warns "Mass Bank Run" is ComingMan who predicted 2023 bank run warns it could soon get worse. Get out of cash and into a new vehicle 50 years in the making. Click here to learn more.September 21, 2023 | americanbankingnews.comCellectar Biosciences (NASDAQ:CLRB) Now Covered by StockNews.comSeptember 18, 2023 | finance.yahoo.comCellectar Biosciences Receives European Medicines Agency Priority Medicines (PRIME) Designation for Iopofosine for Waldenstrom’s MacroglobulinemiaSeptember 18, 2023 | benzinga.comNano-Cap Medical Technology Watchlist (ORHB, BBLG, CLRB, MOVE)September 11, 2023 | benzinga.comCellectar Biosciences Announces Closing of up to Approximately $103 Million Private Placement FinancingSeptember 5, 2023 | marketwatch.comCellectar Biosciences Shares Rise 18% After Private Placement FinancingSeptember 30, 2023 | Chaikin Analytics (Ad)Wall Street Legend Warns "Mass Bank Run" is ComingMan who predicted 2023 bank run warns it could soon get worse. Get out of cash and into a new vehicle 50 years in the making. Click here to learn more.September 5, 2023 | msn.comCellectar Biosciences announces up to ~$103M private placement financingSeptember 5, 2023 | finance.yahoo.comCellectar Biosciences Announces up to Approximately $103 Million Private Placement FinancingAugust 14, 2023 | finanznachrichten.deCellectar Biosciences: Cellectar Reports Financial Results for Second Quarter 2023 and Provides a Corporate UpdateAugust 14, 2023 | finance.yahoo.comCellectar Reports Financial Results for Second Quarter 2023 and Provides a Corporate UpdateJune 28, 2023 | finance.yahoo.comCellectar Biosciences Highlights Promising Interim Data from Its Ongoing Study of Iopofosine I 131 in Multiple Myeloma in an Oral Presentation at the SNMMI Annual MeetingJune 27, 2023 | finance.yahoo.comCLRB - Cellectar Biosciences, Inc.June 12, 2023 | finance.yahoo.comCellectar Provides a Research and Development Program SummaryMay 6, 2023 | morningstar.comUPDATE — Cellectar Reports Financial Results for First Quarter 2023 and Provides a Corporate UpdateMay 6, 2023 | seekingalpha.comCellectar Biosciences GAAP EPS of -$0.76May 4, 2023 | msn.comRecap: Cellectar Biosciences Q1 EarningsMay 4, 2023 | finanznachrichten.deCellectar Biosciences: Cellectar Reports Financial Results for First Quarter 2023 and Provides a Corporate UpdateMay 4, 2023 | finance.yahoo.comCellectar Reports Financial Results for First Quarter 2023 and Provides a Corporate UpdateMay 4, 2023 | finance.yahoo.comUPDATE -- Cellectar Reports Financial Results for First Quarter 2023 and Provides a Corporate UpdateMarch 9, 2023 | finanznachrichten.deCellectar Biosciences: Cellectar Reports Financial Results for Year Ended 2022 and Provides a Corporate UpdateMarch 9, 2023 | finance.yahoo.comCellectar Reports Financial Results for Year Ended 2022 and Provides a Corporate UpdateMarch 1, 2023 | markets.businessinsider.comMaxim Group Keeps Their Buy Rating on Cellectar Biosciences (CLRB)February 28, 2023 | finance.yahoo.comCellectar Biosciences Reports Complete Response in a Relapsed/Refractory CNS Lymphoma PatientFebruary 15, 2023 | finance.yahoo.comCellectar Biosciences Hires Dr. Andrei Shustov as New Senior Vice President, MedicalSee More Headlines Receive CLRB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cellectar Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address CLRB Company Calendar Last Earnings8/14/2023Today9/30/2023Next Earnings (Estimated)11/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CLRB CUSIPN/A CIK1279704 Webwww.cellectar.com Phone(608) 441-8120Fax608-441-8121Employees15Year FoundedN/APrice Target and Rating Average Stock Price Forecast$7.00 High Stock Price Forecast$10.00 Low Stock Price Forecast$4.00 Forecasted Upside/Downside+165.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($3.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-28,600,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-430.14% Return on Assets-204.49% Debt Debt-to-Equity RatioN/A Current Ratio0.87 Quick Ratio0.87 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.51 per share Price / Book1.75Miscellaneous Outstanding Shares9,740,000Free Float8,952,000Market Cap$25.71 million OptionableNot Optionable Beta1.34 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. James V. Caruso (Age 64)Pres, CEO & Director Comp: $846.48kMr. Chad J. Kolean CPA (Age 59)CPA, VP, CFO & Sec. Comp: $453.22kMr. Jarrod Longcor (Age 50)Chief Operating Officer Comp: $625.32kMr. Darrell Shane Lea (Age 50)Chief Commercial Officer Dr. Andrei Shustov M.D. (Age 52)Sr. VP of Medical Key CompetitorsKALA BIONASDAQ:KALAKinetaNASDAQ:KAGenprexNASDAQ:GNPXEquilliumNASDAQ:EQSensei BiotherapeuticsNASDAQ:SNSEView All CompetitorsInstitutional OwnershipWorth Venture Partners LLCSold 23,091 shares on 8/15/2023Ownership: 3.219%Citadel Advisors LLCBought 30,790 shares on 8/15/2023Ownership: 0.316%Renaissance Technologies LLCBought 6,589 shares on 8/11/2023Ownership: 0.657%1900 Wealth Management LLCBought 6,000 shares on 7/21/2023Ownership: 0.185%View All Institutional Transactions CLRB Stock - Frequently Asked Questions Should I buy or sell Cellectar Biosciences stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cellectar Biosciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CLRB shares. View CLRB analyst ratings or view top-rated stocks. What is Cellectar Biosciences' stock price forecast for 2023? 1 brokers have issued 1 year price objectives for Cellectar Biosciences' stock. Their CLRB share price forecasts range from $4.00 to $10.00. On average, they expect the company's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 165.2% from the stock's current price. View analysts price targets for CLRB or view top-rated stocks among Wall Street analysts. How have CLRB shares performed in 2023? Cellectar Biosciences' stock was trading at $1.71 at the start of the year. Since then, CLRB stock has increased by 54.4% and is now trading at $2.64. View the best growth stocks for 2023 here. Are investors shorting Cellectar Biosciences? Cellectar Biosciences saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 482,200 shares, an increase of 238.4% from the August 31st total of 142,500 shares. Based on an average trading volume of 620,200 shares, the short-interest ratio is presently 0.8 days. Approximately 5.2% of the shares of the stock are short sold. View Cellectar Biosciences' Short Interest. When is Cellectar Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. View our CLRB earnings forecast. How were Cellectar Biosciences' earnings last quarter? Cellectar Biosciences, Inc. (NASDAQ:CLRB) issued its quarterly earnings results on Monday, August, 14th. The biopharmaceutical company reported ($0.73) EPS for the quarter, missing analysts' consensus estimates of ($0.69) by $0.04. When did Cellectar Biosciences' stock split? Cellectar Biosciences shares reverse split on Friday, July 22nd 2022. The 1-10 reverse split was announced on Friday, July 22nd 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 22nd 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Cellectar Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectar Biosciences investors own include Hudbay Minerals (HBM), Zynga (ZNGA), Quantum (QTM), Baytex Energy (BTE), Sherritt International (S), Bombardier (BDRBF), Bombardier, Inc. Class B (BBD.B), Bonavista Energy Co. (BNP.TO) (BNP) and Hudbay Minerals (HBM). What is Cellectar Biosciences' stock symbol? Cellectar Biosciences trades on the NASDAQ under the ticker symbol "CLRB." How do I buy shares of Cellectar Biosciences? Shares of CLRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Cellectar Biosciences' stock price today? One share of CLRB stock can currently be purchased for approximately $2.64. How much money does Cellectar Biosciences make? Cellectar Biosciences (NASDAQ:CLRB) has a market capitalization of $25.71 million. The biopharmaceutical company earns $-28,600,000.00 in net income (profit) each year or ($3.32) on an earnings per share basis. How can I contact Cellectar Biosciences? Cellectar Biosciences' mailing address is 100 CAMPUS DRIVE, FLORHAM PARK NJ, 07932. The official website for the company is www.cellectar.com. The biopharmaceutical company can be reached via phone at (608) 441-8120, via email at ir@cellectar.com, or via fax at 608-441-8121. This page (NASDAQ:CLRB) was last updated on 9/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellectar Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.